Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

Let's start with the assumption that $45 MM

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
drkazmd65 Member Profile
 
Followed By 57
Posts 7,675
Boards Moderated 2
Alias Born 02/10/10
160x600 placeholder
NanoViricides reports Q3 results Seeking Alpha - 11/16/2021 7:20:59 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:55:50 PM
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 InvestorsHub NewsWire - 11/15/2021 7:09:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/12/2021 6:16:36 AM
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity InvestorsHub NewsWire - 10/11/2021 6:49:26 AM
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference PR Newswire (US) - 10/5/2021 6:45:00 AM
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference PR Newswire (US) - 10/5/2021 6:45:00 AM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 9/28/2021 4:32:47 PM
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug InvestorsHub NewsWire - 9/22/2021 6:48:40 AM
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug PR Newswire (US) - 9/22/2021 6:45:00 AM
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug PR Newswire (US) - 9/22/2021 6:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/21/2021 11:25:58 AM
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development InvestorsHub NewsWire - 9/14/2021 7:02:10 AM
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development PR Newswire (US) - 9/14/2021 6:53:00 AM
NanoViricides reports strong pre-clinical data for COVID-19 drugs Seeking Alpha - 3/9/2021 11:26:50 AM
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....Cont InvestorsHub NewsWire - 3/9/2021 9:30:00 AM
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical InvestorsHub NewsWire - 3/2/2021 7:00:08 AM
NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies Seeking Alpha - 3/2/2021 6:43:58 AM
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....cont InvestorsHub NewsWire - 2/17/2021 7:00:00 AM
NanoViricides reports FQ2 results Seeking Alpha - 2/17/2021 6:28:57 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/16/2021 4:40:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 9:48:43 AM
NanoViricides’s anti-coronavirus candidate was well tolerated in animal studies Seeking Alpha - 2/8/2021 6:46:46 AM
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C... InvestorsHub NewsWire - 2/8/2021 6:36:27 AM
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants InvestorsHub NewsWire - 1/27/2021 7:00:00 AM
drkazmd65   Thursday, 01/21/16 04:14:21 PM
Re: A deleted message
Post # of 145861 

Let's start with the assumption that $45 MM sales each year for HerpeCide is realistic. Although I have provided reasons as to why it might be significantly greater in a previous message.

The 4x P/E multiplier that is being applied is not nearly the average for revenue generating Drug or Health Care companies.

If you look up P/E ratios in Pharma (in general - http://www.investopedia.com/ask/answers/033015/what-average-pricetoearnings-ratio-drugs-sector.asp) on Investopedia, it states that as of March, 2015 the average P/E ratio in the drugs sector is about 24x. Health Care sector (in general) is >16x.

So even assuming that the gross revenue from HerpeCide is only $45 MM - and that the number of shares is still in the ballpark of 60 MM - the earnings/share would be $0.75 gross. A P/E of 16 would then give a share price of $12/share. A P/E of 24 would then give a share price of $18/share. A P/E of 100x would give a share price of $75/share,.... Not that I anticipate a P/E of 100x is likely.

Assuming that revenues from a HerpeCide are similar from all overseas sources and gross earnings = $90 MM,... then increase share prices based on that accordingly.

I suspect that the 16-24x range is a realistic one to start out once it looks like HerpeCide is ready to hit the market and start drawing in some income - but speculation could easily drive it higer.

And as the revenue from a FluCide comes into play a year or so later,.... what would happen if the gross earnings/share were to run up to $2/share,.... 24 x $2 = $48,....

Given time enough to get some products rolling out and some revenue rolling in,.... $100/share is not at all unreasonable.



“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences